#3
Retatrutide (Triple Agonist, Investigational)
Retatrutide, Eli Lilly's investigational triple GLP-1/GIP/glucagon receptor agonist, achieved a 30.3% average weight loss in the TRIUMPH-1 Phase 3 trial — the highest ever recorded in a randomized obesity trial. At 12 mg weekly over 96 weeks, participants lost approximately 70-71 pounds, with additional benefits including a 75.8% reduction in osteoarthritis pain and a 72% reversal rate of prediabetes. An NDA filing is expected in late 2026, with approval anticipated in 2027; no list price or commercial name is yet available.
0
Photos (1)
Comments on "Retatrutide (Triple Agonist, Investigational)"
Have a take on this ranking?
Comments are how the argument actually happens here. Posting one needs a free account — it takes about a minute.
No comments yet.
The first comment sets the terms of the argument.